Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1)
- Target
- CEACAM1
- Molecular classification
- Immunoglobulin superfamily, Type I transmembrane protein, Cell adhesion molecule
01
Overview
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), also known as CD66a, is a multifunctional glycoprotein and a member of the immunoglobulin superfamily. It plays significant roles in cell adhesion, immune regulation, angiogenesis, and cancer biology. CEACAM1 is a type I transmembrane protein with multiple isoforms generated by alternative splicing and is expressed on epithelial cells, endothelial cells, leukocytes, and various cancer cells. It mediates cell adhesion, modulates immune responses, promotes blood vessel remodeling, and is implicated in tumor progression and metastasis. It interacts with PTPN11 and Annexin A2.
- Other names
- CD66aBGP (biliary glycoprotein)BGP1BGPI
02
Mechanism of action
Immune checkpoint regulation, cell adhesion modulation, angiogenesis modulation
03
Biological functions
Cell adhesionImmune regulationAngiogenesisApoptosis regulationVascular Biology
04
Disease associations
CancerTumor progressionMetastasisInfection
05
Safety considerations
Potential for immune-related adverse events due to immune checkpoint modulation.Complexity of isoforms and their differential roles in cancer progression vs. suppression.
06
Biomarkers
Prognostic marker for malignancy progression/metastasis risk
Beyond the preview
Go deeper on Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1).